NYSE:IQV - Iqvia Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $127.19 +3.10 (+2.50 %) (As of 01/21/2019 04:00 PM ET)Previous Close$124.09Today's Range$124.9050 - $127.6152-Week Range$91.57 - $135.48Volume2.14 million shsAverage Volume1.18 million shsMarket Capitalization$25.44 billionP/E Ratio29.17Dividend YieldN/ABeta0.81 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina. Receive IQV News and Ratings via Email Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Commercial physical research Sub-IndustryN/A SectorBusiness Services Current SymbolNYSE:IQV Previous Symbol CUSIPN/A Webwww.iqvia.com Phone919-998-2000Debt Debt-to-Equity Ratio1.41 Current Ratio1.09 Quick Ratio1.09Price-To-Earnings Trailing P/E Ratio29.17 Forward P/E Ratio24.79 P/E Growth1.62 Sales & Book Value Annual Sales$9.74 billion Price / Sales2.61 Cash Flow$9.7763 per share Price / Cash Flow13.01 Book Value$40.19 per share Price / Book3.16Profitability EPS (Most Recent Fiscal Year)$4.36 Net Income$1.31 billion Net Margins12.29% Return on Equity13.69% Return on Assets4.79%Miscellaneous Employees55,000 Outstanding Shares200,050,000Market Cap$25.44 billion OptionableOptionable Iqvia (NYSE:IQV) Frequently Asked Questions What is Iqvia's stock symbol? Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV." How were Iqvia's earnings last quarter? Iqvia Holdings Inc (NYSE:IQV) posted its quarterly earnings results on Monday, October, 22nd. The medical research company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.39 by $0.03. The medical research company earned $2.59 billion during the quarter, compared to analysts' expectations of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business's quarterly revenue was up 5.2% on a year-over-year basis. View Iqvia's Earnings History. When is Iqvia's next earnings date? Iqvia is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Iqvia. What price target have analysts set for IQV? 16 analysts have issued twelve-month price targets for Iqvia's stock. Their predictions range from $120.00 to $150.00. On average, they anticipate Iqvia's stock price to reach $139.2857 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Iqvia. What is the consensus analysts' recommendation for Iqvia? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia. Has Iqvia been receiving favorable news coverage? News headlines about IQV stock have trended very positive on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iqvia earned a news sentiment score of 3.2 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are some of Iqvia's key competitors? Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Senomyx (SNMX). Who are Iqvia's key executives? Iqvia's management team includes the folowing people: Mr. Ari Bousbib, Chairman, CEO & Pres (Age 58)Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)Mr. Emmanuel N. Korakis, Corp. Controller & Principal Accounting Officer (Age 45) Who are Iqvia's major shareholders? Iqvia's stock is owned by a variety of of institutional and retail investors. Top institutional investors include USS Investment Management Ltd (0.91%), Arvest Bank Trust Division (0.11%), Howard Capital Management (0.06%), DNB Asset Management AS (0.06%), Retirement Systems of Alabama (0.04%) and Sheets Smith Wealth Management (0.03%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Dennis B Ph D Gillings, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks and Ronald A Rittenmeyer. View Institutional Ownership Trends for Iqvia. Which major investors are selling Iqvia stock? IQV stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Nisa Investment Advisors LLC, Gulf International Bank UK Ltd, Meeder Asset Management Inc., Beacon Financial Group, State of Alaska Department of Revenue, First Hawaiian Bank and OLD Second National Bank of Aurora. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks and Ronald A Rittenmeyer. View Insider Buying and Selling for Iqvia. Which major investors are buying Iqvia stock? IQV stock was acquired by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, Blackcrane Capital LLC, First Citizens Bank & Trust Co., Appleton Partners Inc. MA, Chesley Taft & Associates LLC, Altfest L J & Co. Inc., Steward Partners Investment Advisory LLC and Sheets Smith Wealth Management. View Insider Buying and Selling for Iqvia. How do I buy shares of Iqvia? Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Iqvia's stock price today? One share of IQV stock can currently be purchased for approximately $127.19. How big of a company is Iqvia? Iqvia has a market capitalization of $25.44 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe. What is Iqvia's official website? The official website for Iqvia is http://www.iqvia.com. How can I contact Iqvia? Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected] MarketBeat Community Rating for Iqvia (NYSE IQV)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 407 (Vote Outperform)Underperform Votes: 357 (Vote Underperform)Total Votes: 764MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What is a balanced fund?